Article Details

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 ...

Retrieved on: 2021-03-29 05:03:45

Tags for this article:

Click the tags to see associated articles and topics

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 .... View article details on HISWAI: https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19-301257291.html

Excerpt

ceo@nrxpharma.com. INVESTOR RELATIONS Ryan Sheffield rsheffield@nrxpharma.com (484) 254-6134, ext. 723. MEDIA RELATIONS

Article found on: www.prnewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up